MarginsXMarginsX
Home › Markets › Health Care › SCYX

SCYNEXIS Inc. (SCYX)

SCYX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.91
-9.35% on the day
Market cap
$29.0M
Nano cap
Revenue · 2025
$20.6M
+449.9% on 2024
Net income · 2025
-$8.6M
-41.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/0001178253-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSCYX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001178253
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$20.6M
Net income-$8.6M
Operating income-$16.1M
Net margin-41.8%
Operating margin-78.0%
Revenue growth+449.9%
Cash$21.3M
Total assets$59.0M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
8.2 months
$8.2M cash at September 30, 2026
Share count, 1 year
+89.7%
2025-11-01 to 2026-11-01 · +114.0% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$8.2M cash; operating cash flow -$3.0M a quarter.Report 2026-09-30
Shares outstanding9,953,155 (2026-11-01); 41,965,058 a year earlier; 37,207,799 three years earlier. 1y figure adjusted for splits (1-for-8 overall); 3y figure adjusted for splits (1-for-8 overall).Cover page 2026-11-01
Reverse splits, 3 years1; latest 1-for-8 on 2026-06-01Source 2026-06-01
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Morristown, New Jersey, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$8.5M-$7.5M$8.2MNo debt tags$18.9M10-Q 2026-11-05
Q2 2026
2026-06-30
$235K$7.4M-$14.9M$10.5MNo debt tags$19.2M10-Q 2026-08-10
Q1 2026
2026-03-31
$0-$21.3M-$8.1M$36.7MNo debt tags$20.3M10-Q 2026-05-11
Q4 2025
2025-12-31
$18.6M$12.3M$18.4M$21.3MNo debt tags$20.6M10-K 2026-03-04
Q3 2025
2025-09-30
$334K-$8.6M-$8.7M$14.8MNo debt tags$2.9M10-Q 2026-11-05
Q2 2025
2025-06-30
$1.4M-$6.9M-$7.5M$11.0MNo debt tags$3.3M10-Q 2026-08-10
Q1 2025
2025-03-31
$257K-$5.4M-$7.5M$6.9MNo debt tags$2.6M10-Q 2026-05-11
Q4 2024
2024-12-31
$977K-$4.4M-$9.9M$16.1MNo debt tags$3.7M10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-05
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-09-28
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 744 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.3%
1 month-19.5%
3 months-37.3%
Year to date-36.5%
1 year-32.0%
From 52-week high-63.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BCTXBriaCell Therapeutics Corp. Common Shares$3.30-2.65%$28.8M
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.31+0.61%$29.8M
AARDAardvark Therapeutics Inc.$1.26-5.26%$27.6M
NXTCNextCure Inc.$6.68+4.38%$30.6M
NSRXNasus Pharma Ltd.$2.66-7.32%$31.2M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
NNVCNanoViricides Inc.$1.24+0.81%$31.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier